Prevalence of Bronchiectasis in COPD Patients

September 22, 2019 updated by: Aliae AR Mohamed Hussein, Assiut University

Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assiut, Egypt, 71111
        • Recruiting
        • AssiutU
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

COPD patients diagnosed based on GOLD criteria 2019 with chest CT finding of bronchiectasis

Description

Inclusion Criteria:

  • COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion Criteria:

  • acute pneumonia within 2 months
  • malignancy
  • congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A
COPD patients with bronchiectasis
Other: prevalence
percentage of bronchectasis in COPD and its effect as prognostic measure
Group B
COPD patients without bronchiectasis
Other: prevalence
percentage of bronchectasis in COPD and its effect as prognostic measure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Bronchiectasis in COPD
Time Frame: 1 year
percentage of bronchiectasis diagnosed by CT chest in COPD patients
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
impact of bronchiectasis on COPD exacerbations
Time Frame: 1 year
number of exacerbations treated in or out of hospitals
1 year
impact of bronchiectasis on COPD hospitalization
Time Frame: 1 year
number of hospital admissions with acute exacerbations
1 year
impact of bronchiectasis on COPD intensive care admission
Time Frame: 1 year
number of admissions in respiratory ICU and need for mechanical or non invasive ventilation
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 30, 2019

Primary Completion (Anticipated)

September 1, 2020

Study Completion (Anticipated)

September 30, 2020

Study Registration Dates

First Submitted

September 22, 2019

First Submitted That Met QC Criteria

September 22, 2019

First Posted (Actual)

September 24, 2019

Study Record Updates

Last Update Posted (Actual)

September 24, 2019

Last Update Submitted That Met QC Criteria

September 22, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AssiutU7

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiectasis

Clinical Trials on prevalence

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe